OTC Medicines

The Consumer Healthcare Products Association (CHPA) released the following statement in advance of FDA Advisory Committee meetings considering OTC access to naloxone

Don't miss CHPA President & CEO, Scott Melville's insights on the consumer healthcare industry for the year ahead. Check out this article from Chain Drug Review.

CHPA applauds the passage of the Fiscal Year 2023 omnibus appropriations bill, which includes several CHPA-backed measures.

Since mid-November 2022, CHPA's messages about the supply of children's pain-relief and fever-reducing medicines have appeared in over 1,400 news stories.

Manufacturers continue operating at maximum capacity to replenish children’s pain and fever reducers to meet current extraordinary demand. While there is not a widespread shortage and our member companies are continuously shipping out products to retailers to replenish supply as quickly as possible, we recognize that limited products on store shelves is frustrating for parents and caregivers.

The annual Monitoring the Future survey, conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA), shows that the percentage of adolescents reporting substance use in 2022 “held steady” following significant overall declines in 2021. This year’s findings are particularly meaningful following historic declines last year, especially since most teens returned to school, to extracurricular activities, and to other social engagements in 2022 after nearly two years of social distancing.